The American Journal of Medicine
Volume 121, Issue 1 , Pages 3-9 , January 2008

Alpha-1 Antitrypsin Deficiency: Pathogenesis, Clinical Presentation, Diagnosis, and Treatment

  • Thomas Köhnlein, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Thomas Köhnlein, MD, Hannover Medical School, Department of Respiratory Medicine, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.
    • ,
  • Tobias Welte, MD, PhD

References 

  1. Luisetti M, Seersholm N. Alpha-1antitrypsin deficiency. 1: Epidemiology of alpha-1 antitrypsin deficiency. Thorax. 2004;59:164–169
  2. van Steenbergen W. Alpha-1 antitrypsin deficiency: an overview. Acta Clin Belg. 1993;48:171–189
  3. Williams SE, Brown TI, Roghanian A, Sallenave JM. SLPI and elafin: one glove, many fingers. Clin Sci (Lond). 2006;110:21–35
  4. Blanco I, de Serres FJ, Fernandez-Bustillo E, et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J. 2006;27:77–84
  5. Tobin MJ, Cook PJ, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z—a survey by the British Thoracic Association. Br J Dis Chest. 1983;77:14–27
  6. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986;89:370–373
  7. Purkayastha P, Klemke JW, Lavender S, et al. Alpha-1 antitrypsin polymerization: a fluorescence correlation spectroscopic study. Biochemistry. 2005;44:2642–2649
  8. Ogushi F, Fells GA, Hubbard RC, et al. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987;80:1366–1374
  9. Perlmutter DH. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res. 2006;60:233–238
  10. Röcken C, Peitz U. Liver Disease in Alpha-1 Antitrypsin Deficiency. In:  Köhnlein T,  Welte T editor. Alpha-1 Antitrypsin Deficiency (Clinical Aspects and Management). Uni-Med: Bremen; 2006;p. 40–44
  11. Morse JO. Alpha-1 antitrypsin deficiency. N Engl J Med. 1978;299:1045–1048
  12. Needham M, Stockley RA. Alpha 1-antitrypsin deficiency (3: Clinical manifestations and natural history). Thorax. 2004;59:441–445
  13. Hadzic R, Nita I, Tassidis H, et al. Alpha-1 antitrypsin inhibits Moraxella catarrhalis MID protein-induced tonsillar B cell proliferation and IL-6 release. Immunol Lett. 2006;102:141–147
  14. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol. 1998;18:670–674
  15. Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol. 2005;166:377–386
  16. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency (2: Genetic aspects of alpha 1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk). Thorax. 2004;59:259–264
  17. Wittes J, Wu MC. Natural History of Alpha-1 Antitrypsin Deficiency. In:  Crystal RG editors. Alpha-1 Antitrypsin Deficiency. Marcel Dekker: New York; 1996;p. 281–291
  18. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha-1 antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001;164:1805–1809
  19. Pauwels RA, Buist AS, Calverley PM, et al. GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary). Am J Respir Crit Care Med. 2001;163:1256–1276
  20. Schwaiblmair M, Beinert T, Seemann M, et al. Relations between cardiopulmonary exercise testing and quantitative high-resolution computed tomography associated in patients with alpha-1-antitrypsin deficiency. Eur J Med Res. 1998;3:527–553
  21. Emerick KM, Whitington PF. Neonatal liver disease. Pediatr Ann. 2006;35:280–286
  22. Perlmutter DH. Alpha-1-antitrypsin deficiency: diagnosis and treatment. Clin Liver Dis. 2004;8:839–859
  23. Eriksson S, Carlson J, Verlez R. Risk of cirrhosis and primary liver cancer in alpha-1 antitrypsin deficiency. N Engl J Med. 1986;314:736–739
  24. Hussain M, Mieli-Vergani G, Mowat AP. Alpha 1-antitrypsin deficiency and liver disease: clinical presentation, diagnosis and treatment. J Inherit Metab Dis. 1991;14:497–511
  25. Elzouki AN, Segelmark M, Wieslander J, Eriksson S. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener’s granulomatosis. J Intern Med. 1994;236:543–548
  26. Ortiz PG, Skov BG, Benfeldt E. Alpha1-antitrypsin deficiency-associated panniculitis: case report and review of treatment options. J Eur Acad Dermatol Venereol. 2005;19:487–490
  27. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900
  28. Brantly M. Laboratory Diagnosis of Alpha-1 Antitrypsin Deficiency. In:  Crystal RG editors. Alpha-1 Antitrypsin Deficiency. Marcel Dekker: New York; 1996;p. 211–226
  29. Köhnlein T, Klein H, Welte T. Alpha 1-protease inhibitor deficiency (Diagnosis, follow-up and therapy options). Med Klin. 1999;7:371–376
  30. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57:15–19
  31. Fabbri LM, Luppi F, Beghe B, Rabe KF. Update in chronic obstructive pulmonary disease 2005. Am J Respir Crit Care Med. 2006;173:1056–1065
  32. Calverley P, Anderson JA, Celli B, et al. TORCH Study Group Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2007;356:775–789
  33. Wijkstra PJ. Non-invasive positive pressure ventilation (NIPPV) in stable patients with chronic obstructive pulmonary disease (COPD). Respir Med. 2003;97:1086–1093
  34. Currie GP, Douglas JG. ABC of chronic obstructive pulmonary disease (Non-pharmacological management). BMJ. 2006;332:1379–1381
  35. Teschler H, Stamatis G, el-Raouf Farhat AA, et al. Effect of surgical lung volume reduction on respiratory muscle function in pulmonary emphysema. Eur Respir J. 1996;9:1779–1784
  36. Wencker M, Banik N, Buhl R, et al. Long-term treatment of alpha-1 antitrypsin deficiency-related pulmonary emphysema with human alpha-1 antitrypsin. Eur Respir J. 1998;11:428–433
  37. Barker AF, Siemsen F, Pasley D, et al. Replacement therapy for hereditary alpha-1antitrypsin deficiency (A program for long-term administration). Chest. 1994;105:1406–1410
  38. Seersholm N, Wencker M, Banik N, et al. Does alpha-1 antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha-1 antitrypsin deficiency?. Eur Respir J. 1997;10:2260–2263
  39. Alpha 1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha-1-antitrypsin. Am J Respir Crit Care Med. 1998;158:49–59
  40. Abboud RT, Ford GT, Chapman KR. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?. Treat Respir Med. 2005;4:1–8
  41. Dirksen A. EXACTLE. Introduction to the study protocol. Annual Congress of the European Respiratory Society, Munich, 04.09.2006, oral presentation.

PII: S0002-9343(07)00736-X

doi: 10.1016/j.amjmed.2007.07.025

The American Journal of Medicine
Volume 121, Issue 1 , Pages 3-9 , January 2008

Article Tools

* Image Usage & Resolution